| Literature DB >> 32350952 |
Yuhei Fujisawa1, Satoshi Hara1, Takeshi Zoshima1, Naoto Maekawa2, Dai Inoue3, Motoko Sasaki4, Tadatsugu Gamou2, Yoji Nagata2, Kenshi Hayashi2, Akari Takeji1, Kiyoaki Ito1, Ichiro Mizushima1, Hiroshi Fujii1, Mitsuhiro Kawano1.
Abstract
Mucormycosis is a rare fungal infection occurring in the immunocompromised host. It is difficult to diagnose, and its cardiac involvement is extremely rare. Here, we report a 64-year-old Japanese man with a 5-year history of hemodialysis with disseminated mucormycosis causing fulminant myocarditis and pulmonary necrosis under glucocorticoid use. Two months before, he had received an implantable cardioverter defibrillator and started to take amiodarone for recurrent ventricular arrhythmias due to hypertensive cardiomyopathy. He developed amiodarone-induced interstitial pneumonia and then received glucocorticoid therapy. Although the interstitial pneumonia partially improved, a lung cavitary lesion developed in the upper right lobe. Antibiotics had no effect, and serologic tests, blood and sputum cultures and bronchoalveolar lavage fluid were all negative for infectious pathogens. Eventually, he died of fulminant myocarditis. Autopsy revealed disseminated mucormycosis with vascular invasion and fungal thrombi, hemorrhage and infarction in lung (cavity lesion), heart (severe myocarditis), brain, thyroid and subcutaneous tissue around the implantable cardioverter defibrillator. The lung cavitary lesion was the only clinical finding suggestive of mucormycosis before autopsy. When an immunocompromised patient shows a progressive lung cavity lesion, the possibility of mucormycosis should be considered so that a broad-spectrum antifungal agent can be empirically administered in a timely fashion.Entities:
Keywords: disseminated mucormycosis; fulminant myocarditis; glucocorticoid; hemodialysis; pulmonary cavity lesion
Mesh:
Substances:
Year: 2020 PMID: 32350952 DOI: 10.1111/pin.12943
Source DB: PubMed Journal: Pathol Int ISSN: 1320-5463 Impact factor: 2.534